Mid‐term clinical outcomes from use of Sirolimus coated balloon in coronary intervention; data from real world population

Abstract

The results from mid-term follow-up with this relatively new technology SCB is encouraging with a low rates of hard endpoints and acceptable MACE rates despite complex group of patients and lesion subsets.